Fate Therapeutics' Stem Cell-Derived NK Lymphoma Candidate Casts Doubt Over Durability Of Response

  • Fate Therapeutics Inc FATE revealed an early cut of Phase I data for its FT596 and FT516 programs for relapsed / refractory B-cell lymphoma.
  • At the 2021 American Society of Clinical Oncology Meeting, the Company highlighted positive interim FT516 program data for 11 pretreated patients.
  • Related: Fate Therapeutics Shares Positive B-Cell Lymphoma Data at ASCO21.
  • At a three-month check-in, eight of 11 B cell lymphoma patients who received FT516 reported an objective response with no major safety signals. 
  • But at a July 7 cutoff, just five patients (45%) maintained those responses, with two complete responders seeing their disease progress and a partial responder forced to receive an “additional anti-cancer therapy.”
  • FT516’s results in patients with prior CD19 CAR-T therapy, two of four posted a complete response, spurring Fate to announce a dose-expansion cohort in that population.
  • Meanwhile, FT596 posted early data of its showing promising efficacy.
  • Interim data showed that 10 of 14 patients across two dose-escalation cohorts posted an objective response, including seven complete responders, including two of three patients treated with a combo of FT596 and Rituxan after autologous CD19 CAR-T therapy.
  • Fate expects to present further data from both studies at the upcoming ASH conference in December, including a first look at the durability of response for FT596.
  • Price Action: FATE shares closed 5.90% lower at $85.63 on Thursday.

Posted In: BriefslymphomaPhase 1 TrialBiotechNewsHealth CareMoversTrading IdeasGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.